Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 1, 2018 4:05 PM EDTMENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended September 30, 2018.
Financial Highlights
Revenue of $64.4 million, a 51 percent increase from third quarter 2017GAAP net income of $0.14 per share, compared to $0.11 per share in third quarter 2017Non-GAAP net income of $0.22 per share, compared to... More